Medicare GLP-1 Coverage in 2026: What It Means for Pricing
💊 The Bottom Line
For the first time, Medicare is covering GLP-1 medications for weight loss. But it's not as simple as "Medicare now covers Wegovy." Here's the timeline:
- July 1, 2026: Medicare GLP-1 Bridge launches — eligible beneficiaries pay $50/month for Wegovy or Zepbound
- January 1, 2027: BALANCE Model launches in Medicare Part D — GLP-1s become part of the standard Part D benefit for participating plans
- Both are demonstration programs, not permanent benefit changes. Congress has not passed legislation permanently adding obesity drugs to Medicare.
Why Medicare GLP-1 Coverage Is a Big Deal
Until now, Medicare Part D has explicitly excluded drugs prescribed solely for weight loss. That exclusion has been in place for decades. Medicare has covered GLP-1 medications like Ozempic when prescribed for type 2 diabetes, but Wegovy and Zepbound — the obesity-specific versions — were not covered, period.
This matters enormously because obesity affects roughly 40% of adults aged 65 and older. With GLP-1 medications costing $300–$1,349/month at list price, most Medicare beneficiaries on fixed incomes simply couldn't afford them. The result: a massive population with the highest need had the least access.
The two programs launching in 2026-2027 change this — cautiously, experimentally, but meaningfully.
Program 1: The Medicare GLP-1 Bridge (July 2026)
This is a short-term demonstration that runs from July 1, 2026 through December 31, 2026. It serves as a bridge to the larger BALANCE Model.
Key Details
- Cost to beneficiary: $50/month for eligible GLP-1 medications
- Eligible medications: Wegovy and Zepbound (FDA-approved for weight reduction)
- Nationwide: Available in all states and territories
- No plan opt-in required: Your Part D plan does not need to participate. CMS administers this directly, outside the normal Part D benefit structure.
- Part D sponsors carry no risk: This operates entirely outside the Part D benefit — plan sponsors don't bear any financial risk for GLP-1 costs during the Bridge.
- Prior authorization required: Your provider must submit a PA request and prescription. CMS is using a single central processor for all PA and claims under the Bridge.
Who's Eligible
You must be enrolled in a Medicare Part D plan (either standalone PDP or Medicare Advantage with prescription drug coverage). You must meet the prior authorization criteria, which CMS is finalizing in Spring 2026. Based on available guidance, expect criteria similar to standard obesity treatment eligibility: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity.
Important for low-income beneficiaries: The Low-Income Subsidy (LIS) cost-sharing reductions do not apply to the Medicare GLP-1 Bridge. That means even LIS-eligible beneficiaries will pay the $50/month copay. For beneficiaries on tight budgets, this is worth factoring in.
Program 2: The BALANCE Model (January 2027)
BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) is a larger, longer-term CMS Innovation Center demonstration. It's the more permanent-looking framework.
Key Details
- Medicare Part D launch: January 1, 2027
- Medicaid launch: As early as May 2026 for participating states
- How it works: CMS negotiates drug pricing directly with GLP-1 manufacturers. Those negotiated prices flow through to participating Part D plans and Medicaid programs.
- Voluntary for all parties: Manufacturers, states, and Part D plans all choose whether to participate
- Lifestyle component: Participating beneficiaries get access to lifestyle interventions (nutrition counseling, exercise programs) provided by drug manufacturers at no additional cost
- Duration: Model testing runs through December 2031
The Transition Problem
There's a gap that beneficiaries need to plan for. The Medicare GLP-1 Bridge ends December 31, 2026. BALANCE starts January 1, 2027 — but only for Part D plans that opted in. If your current Part D plan doesn't participate in BALANCE, you'll need to switch to one that does during Medicare Open Enrollment (October 15 – December 7, 2026) to maintain coverage.
This is critical: if you start a GLP-1 through the Bridge program, check whether your plan is participating in BALANCE before the end of 2026. If not, you'll need to switch plans or lose coverage of your GLP-1 for weight management.
The Cost Comparison for Medicare Beneficiaries
| Scenario | Monthly Cost | Annual Cost |
|---|---|---|
| Before July 2026: No Medicare coverage for weight-loss GLP-1s | $299–$1,349 (self-pay) | $3,588–$16,188 |
| July–Dec 2026: Medicare GLP-1 Bridge | $50 | $300 (6 months) |
| January 2027+: BALANCE Model (Part D) | TBD (negotiated) | TBD |
| January 2027: IRA-negotiated Ozempic | ~$274 | ~$3,288 |
What You Should Do Right Now
If You're a Medicare Beneficiary Interested in GLP-1s
- Talk to your doctor now. Get your BMI documented and any weight-related comorbidities on record. This prepares you for the prior authorization process when the Bridge launches in July.
- Verify your Part D plan. Call the number on your Medicare card and ask whether they plan to participate in the BALANCE Model for 2027. If they don't know yet, check back in late summer.
- Watch for the Spring 2026 CMS updates. The prior authorization process, pharmacy details, and eligible medication list will be released then. Monitor Medicare.gov for announcements.
- Consider starting now at self-pay if you can afford it. NovoCare offers Wegovy injectable at $349/month and the Wegovy pill at $149/month. Starting treatment before July means you'll already be at your therapeutic dose when Medicare coverage kicks in, rather than spending months in dose titration.
Sesame Care
Get a GLP-1 prescription with a licensed provider — telehealth consultations available now
Check Eligibility → From $175If You're Already on a Compounded GLP-1
The Medicare GLP-1 Bridge only covers FDA-approved medications (Wegovy, Zepbound). Compounded GLP-1s are not eligible. If you're currently on a compounded product and have Medicare, July 2026 is your transition point to brand-name — at $50/month, there's no financial reason to stay on compounded medication.
The Bigger Picture
It's important to be precise about what these programs are and aren't. They are CMS demonstration programs — not permanent benefit changes. Congress has not passed the Treat and Reduce Obesity Act or any other legislation permanently adding obesity treatment to Medicare. Bills like the AOMT Act have been introduced but not enacted.
CMS is using demonstration authority to gather real-world data that lawmakers have historically demanded before making permanent changes. If the Bridge and BALANCE programs demonstrate improved health outcomes and manageable costs, they strengthen the case for permanent legislation. If they don't, coverage could contract.
For now, the practical reality is that millions of Medicare beneficiaries who couldn't access GLP-1 medications for weight loss will have a $50/month pathway starting in July 2026. That's a genuinely historic shift, even if it's technically temporary.
Medicaid Coverage: State by State
Medicaid operates differently from Medicare — coverage decisions happen at the state level. As of January 2026, only about 13 states provide Medicaid coverage for GLP-1 medications prescribed for obesity (down from 16 in 2025, reflecting state budget pressures).
The BALANCE Model opens participation to state Medicaid programs starting May 2026 on a rolling basis. States that opt in will get negotiated pricing through supplemental rebate agreements with manufacturers, with standardized coverage criteria set by CMS. States can offer broader coverage than the minimum but cannot make criteria more restrictive.
If you're on Medicaid, check with your state's Medicaid office to see if they've opted into the BALANCE Model. Coverage varies dramatically by state, and this model could change access in states that currently don't cover obesity medications.